BIOMAT Database Logo BIOMAT Database Logo

Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. 2002

Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Division of Infectious Diseases, Children's Memorial Hospital, Chicago, IL 60614-3394, USA. r-yogev@northwestern.edu

BACKGROUND The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine (d4T), nevirapine (NVP) and ritonavir (RTV) has not been determined. Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination. METHODS During a clinical trial in which HIV-infected antiretroviral-experienced children were initially randomized to receive d4T/RTV, ZDV/3TC/RTV or ZDV/3TC (Step 1), 48 children who had HIV RNA > or = 10,000 copies/ml after > or = 12 weeks of ZDV/3TC therapy in Step 1 were switched to d4T/NVP/RTV in Step 2. The proportion of children receiving therapy with HIV RNA < or = 400 copies/ml at Study Weeks 24 and 48 receiving d4T/NVP/RTV in Step 2 were compared with children receiving RTV-containing regimens in Step 1. RESULTS At 24 weeks of treatment with d4T/NVP/RTV in Step 2, 48% (23 of 48) of children had HIV RNA < or = 400 copies/ml compared with 34% (31 of 92) and 47% (44 of 93) receiving d4T/RTV or ZDV/3TC/RTV for 24 weeks in Step 1; at 48 weeks virologic response was 44, 27 and 42% in Step 2 d4T/NVP/RTV, Step 1 d4T/RTV and Step 1 ZDV/3TC/RTV arms, respectively. CONCLUSIONS A delay of 7 to 12 months in the initiation of protease inhibitor-containing combination therapy in children receiving dual nucleoside analogue therapy did not adversely affect the RNA response during the first 48 weeks of treatment.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
April 2004, Pharmacotherapy,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.
May 2002, Archives of pediatrics & adolescent medicine,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
[A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
August 2003, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
January 1999, AIDS (London, England),
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
CD4(+) T Cell Response to Lamivudine, Stavudine and Nevirapine in Human Immunodeficiency Virus Infected Antiretroviral-Naive Men in Nigeria.
December 2011, Indian journal of virology : an official organ of Indian Virological Society,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
March 2001, The Journal of infectious diseases,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Antiretroviral therapy for infection due to human immunodeficiency virus in children.
October 1994, Pediatric AIDS and HIV infection,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Antiretroviral therapy for infection due to human immunodeficiency virus in children.
July 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Stavudine-induced macrocytosis during therapy for human immunodeficiency virus infection.
August 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Ram Yogev, and Sophia Lee, and Andrew Wiznia, and Sharon Nachman, and Kenneth Stanley, and Stephen Pelton, and Lynne Mofenson, and Susan Fiscus, and Eleanor Jimenez, and Mobeen H Rathore, and Mary Elizabeth Smith, and Lin Ye Song, and Kenneth McIntosh, and
Antiretroviral treatment for children with human immunodeficiency virus infection.
August 1991, Pediatrics,
Copied contents to your clipboard!